Your browser doesn't support javascript.
loading
Activating KIR Haplotype Influences Clinical Outcome Following HLA-Matched Sibling Hematopoietic Stem Cell Transplantation.
Heatley, S L; Mullighan, C G; Doherty, K; Danner, S; O'Connor, G M; Hahn, U; Szer, J; Schwarer, A; Bradstock, K; Sullivan, L C; Bardy, P G; Brooks, A G.
Afiliação
  • Heatley SL; University of Melbourne, Melbourne, Vic, Australia.
  • Mullighan CG; Australian Red Cross Blood Service, Adelaide, SA, Australia.
  • Doherty K; St Jude Children's Research Hospital, Memphis, TN, USA.
  • Danner S; Australian Red Cross Blood Service, Adelaide, SA, Australia.
  • O'Connor GM; Australian Red Cross Blood Service, Adelaide, SA, Australia.
  • Hahn U; Royal Adelaide and Queen Elizabeth Hospitals, SA Pathology, Adelaide, SA, Australia.
  • Szer J; University of Melbourne, Melbourne, Vic, Australia.
  • Schwarer A; Royal Adelaide and Queen Elizabeth Hospitals, SA Pathology, Adelaide, SA, Australia.
  • Bradstock K; University of Melbourne, Melbourne, Vic, Australia.
  • Sullivan LC; Royal Melbourne Hospital, Melbourne, Vic, Australia.
  • Bardy PG; Alfred Hospital, Melbourne, Vic, Australia.
  • Brooks AG; Westmead Hospital, Sydney, NSW, Australia.
HLA ; 2018 Jun 25.
Article em En | MEDLINE | ID: mdl-29943500
ABSTRACT
Natural killer cells are thought to influence the outcome of hematopoietic stem cell transplant (HSCT), impacting on relapse, overall survival, graft versus host disease and the control of infection, in part through the complex interplay between the large and genetically diverse killer immunoglobulin-like receptor (KIR) family and their ligands. This study examined the relationship between KIR gene content and clinical outcomes including the control of opportunistic infections such as cytomegalovirus in the setting of human leucocyte antigen (HLA)-matched sibling HSCT in an Australian cohort. The presence of the KIR B haplotype which contain more activating receptors in the donor, in particular centromeric B haplotype genes (Cen-B), was associated with improved overall survival of patients with acute myeloid leukemia (AML) undergoing sibling HSCT and receiving myeloablative conditioning. Donor Cen-B haplotype was also associated with reduced acute graft versus host disease grades II-IV whereas donor telomeric-B haplotype was associated with decreased incidence of CMV reactivation. In contrast, we were not able to demonstrate a reduced rate of relapse when the donor had KIR Cen-B, however relapse with a donor Cen-A haplotype was a competing risk factor to poor overall survival. Here we show that the presence of donor activating KIR led to improved outcome for the patient, potentially through reduced relapse rates and decreased incidence of acute GvHD translating to improved overall survival. This article is protected by copyright. All rights reserved.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: HLA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: HLA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Austrália